Quadrivalent Influenza Vaccine Secures China Distribution

Clover Biopharmaceuticals, Ltd. today announced that it entered into an exclusive agreement with Taiwan-based Adimmune Corporation for Clover to distribute AdimFlu-S (QIS), a quadrivalent split inactivated vaccine, in mainland China.

The China National Medical Products Administration approved AdimFlu-S (QIS) in January 2022 for individuals three years and older.

AdimFlu-S (QIS) is currently the only imported quadrivalent seasonal influenza vaccine approved for use in China for individuals three years and older.

With commercial launch forecasted for later in 2023.

The agreement also grants Clover rights to commercialize AdimFlu-S (QIS) in Bangladesh, Brazil, and the Philippines, contingent on local regulatory approvals.

“We are very pleased to partner with Clover, with its growing commercial presence in mainland China and impressive record of successful cross-border collaboration,” said Dr. Chi-Hsien Chan, Chairman and Chief Executive Officer of Adimmune, in a Clover press release on February 19, 2023.

As a quadrivalent vaccine, AdimFlu-S (QIS) contains hemagglutinin from four influenza virus strains (two A and two B).

Clover Biopharmaceuticals is a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health worldwide. 

Founded in 1965, Adimmune Corporation is the only influenza vaccine manufacturer with both EU GMP and US FDA certificates in Taiwan.